DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Untch M, Fasching PA, Konecny GE. et al.
Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
J Clin Oncol 2011;
29: 3351-3357
We do not assume any responsibility for the contents of the web pages of other providers.